Interim report in brief: Inhalation Sciences increased sales during the reporting period compared to the corresponding period last year by approx. 229 percent, contracted a CRO to conduct a clinical study of the PreciseInhale system, financed the clinical trial in its entirety through the sale of shares in the associated company Ziccum AB and, during the third quarter, recruited a new CEO: Mr. Manoush Masarrat.
Inhalation Sciences ships PreciseInhale order worth 1.5 MSEK to Asia, delivering 209% yearly sales increase
(Stockholm Nov 1, 2019) Inhalation Sciences (ISAB) has successfully shipped a PreciseInhale to Singapore, in a second order from an existing customer worth 1.5 MSEK. CEO Manoush Masarrat: “This order brings our sales figures up to and including October 2019 to 6.8 MSEK, an increase of 209% compared to the same period in 2018.”
September 27, Stockholm, Sweden: With over 15 years’ leadership experience in Medtech, Manoush Masarrat is the new CEO of Inhalation Sciences, taking over the full executive and operational running of the company at short notice after 10 months as a Board member. So how has it been to move straight from the Board to the Lab, and how have his first two weeks as CEO been?
Inhalation Sciences' PreciseInhale delivers exceptional precision in ground-breaking inhalable nicotine study
September 24, Stockholm, Sweden. In a ground-breaking publication on inhalable nicotine PreciseInhale aerosol technology revealed new data on the drug’s pharmacokinetic behavior that until now was unobtainable. ISAB CEO Manoush Masarrat: “The strategic value of data of this precision is immense. It enables drug developers to establish a failsafe strategy for their inhaled medications from day one.”
STOCKHOLM, SWEDEN – 13 September, 2019. Inhalation Sciences, which develops and commercializes world-leading instruments for inhalation research, today announces that Manoush Masarrat will be appointed new CEO. Manoush is currently a member of the company's Board of Directors. He has extensive knowledge of the company's products and strategy. Manoush's first day as CEO will be September 16 2019.
Inhalation Sciences (ISAB), which develops and commercializes world-leading instruments for inhalation research, today announces that it intends to replace its CEO. The company intends to announce the name of its new CEO next week. For the present Lena Heffler will continue as the company’s CEO.
(Stockholm August 23 2019) Inhalation Sciences Sweden AB has received an order for a new PreciseInhale system from an existing customer with global lab facilities. The new order includes a range of exposure modules and PreciseInhale’s new customized nebulizer feature.
Inhalation Sciences CEO Lena Heffler: “A major milestone was reached this quarter with the announcement that we’re commencing a new Study validating PreciseInhale for clinical use. We also received a purchase order for a second PreciseInhale system from a client, a landmark for the company. With clinical validation started and DissolvIt on the way towards commercialization, our goal continues to be achieving cash flow positive results on a full-year basis during 2020.”
(Stockholm August 5, 2019) Inhalation Sciences (ISAB) is conducting a Contract Research Order feasibility study worth 1 MSEK for a leading European inhaled pharmaceutical developer. ISAB was chosen because of its unique ability to deliver predictive, voluminous data from tiny amounts of challenging substance in nebulized as well as dry powder aerosol.
Inhalation Sciences AB and Clinical Trial Consultants AB collaborate on clinical validation of PreciseInhale
STOCKHOLM, SWEDEN – July 1, 2019. Inhalation Sciences AB (ISAB) has contracted Swedish CRO Clinical Trials Consultants AB to carry out its clinical study validating PreciseInhale for clinical use. CTC CEO Anders Millerhovf: “For us this is a win-win. As an innovation-focussed CRO we appreciate the new value and data that a clinically validated PreciseInhale system will offer the inhalation industry and we look forward to continuing to explore PreciseInhale’s highly competitive capabilities”.
(STOCKHOLM, SWEDEN - May 23, 2019) The Board of Inhalation Sciences (ISAB) has decided to initiate and invest in a clinical study to validate PreciseInhale for clinical use. Technical and regulatory validation is expected to take about 15 months, and will be fully financed through the divestment of a small part of ISAB's holdings in Ziccum AB.
CEO Lena Heffler: “Strong scientific publications have confirmed our technology as leading in preclinical inhalation research, we are moving towards taking PreciseInhale into the clinical arena and our capital base has strengthened through the listing of our subsidiary Ziccum AB on Spotlight.”
(Stockholm May 7, 2019) Inhalation Sciences (ISAB) has received an order for a PreciseInhale® system, including the platform's unique integrated inhaler actuator, from an existing customer within the inhalation arena. The order is worth approx. 1.6 million SEK.
(Stockholm April 15 2019) Inhalation Sciences AB today announces that the Annual Report for 2018 is now available on the company’s website.
CEO Lena Heffler: “During the past year ISAB has passed several significant milestones. All these are clear signals that our vision – that PreciseInhale will become the standard tool for Inhalation Research and Development worldwide – is within reach”.
December 19, Stockholm, Sweden. The order, worth 0.25 MSEK, follows a successful earlier collaboration. ISAB CEO Lena Heffler: “Customers as large and innovative as this one returning to carry out more projects shows clearly how outstanding our data is, and the control and precision it delivers.”
Inhalation Sciences (ISAB) has received an order for a PreciseInhale system, and DissolvIt, the system’s unique in vitro module for studying particle dissolution. The order is initially valued at approximately 2.0 MSEK.
Inhalation Sciences’ CEO Lena Heffler’s presentation will also be streamed live. “The world-leading control and precision of our technology means lung scientists save crucial time and money in essential early-stage research. I look forward to showing investors how far we’ve already come.”
Summary of Interim Report, first nine months 2018: Orders were received during the third quarter for PreciseInhale and CRO assignments totalling more than 5 MSEK, a record for the company in a single quarter. During the reporting period the subsidiary Ziccum carried out a successful listing process, which after the end of the quarter resulted in a share issue which raised 15.8 MSEK and was listed on Spotlight Stock Market. Earlier in the year Lena Heffler succeeded Fredrik Sjövall as new CEO, the European Patent Office EPO gave approval notice on one of Inhalation Sciences’ most important patents, and the company received 2 MSEK of EU funding within the FORMAMP framework, a research project targeted at developing new antibacterial-resistant therapies
STOCKHOLM, SWEDEN 9 October. On October 3, 2018, the subscription period for Ziccum's new issue of units was completed, prior to its planned listing on Spotlight. The new issue of 15.8 MSEK was subscribed to approximately 52.7 MSEK including subscription commitments, a subscription ratio of approximately 334%. Ziccum will therefore receive a total of 15.8 MSEK before issue costs of approx. 1 MSEK, while increasing the number of shareholders to approximately 1000. Settlement notes for units subscribed without preference under the new terms and conditions was issued on October 8, 2018.
Stockholm, Sweden 8 October: The European Patent Office has granted a patent to XposeALI, ISAB’s in vitro cell culturing module. “XposeALI delivers exceptionally precise, detailed data on how airborne micro- and nanoparticles particles affect cells in the lung, early on—whilst dramatically reducing the number of animals needed in research,” says ISAB CEO Lena Heffler.
September 19, STOCKHOLM. Inhalation Sciences (ISAB) has received an order for a PreciseInhale system, together with two of its in vitro exposure modules. The order is initially worth apoprox. 2.4 MSEK.
STOCKHOLM, SWEDEN – 14 September, 2018. Inhalation Sciences subsidiary Ziccum has been approved for listing on Stockholm stock market Spotlight, provided that the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue will begin on September 19 and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.
Inhalation Sciences in 3-year research project with 5 organizations, including purchase of new PreciseInhale system by Chiesi
STOCKHOLM, SWEDEN – July 31, 2018. Inhalation Sciences (ISAB) will collaborate in an extensive research project with RCPE (Research Center Pharmaceutical Engineering) in Graz, Austria, the Medical University of Graz, Technical University (Graz) and Italian pharmaceutical company Chiesi. Chiesi has signed a Capital Expenditure Clause for the purchase of a new PreciseInhale system to be used in the project, which has an initial value of 0.9 MSEK.
Inhalation Sciences gets PreciseInhale order from Westchina-Frontier Pharma Tech Co. Ltd. (WCFP), a leading Chinese CRO.
Inhalation Sciences (ISAB) has received an order from the Chinese CRO Westchina-Frontier Pharma Tech Co,. Ltd.(WCFP) on a PreciseInhale system, including its modules for in vivo studies. The order value is initially approx. 1.2 MSEK.
Inhalation Sciences subsidiary Ziccum awarded 0.5 MSEK from Horizon 2020—the EU’s biggest Research and Innovation program
(STOCKHOLM 18-07-11) The 0.5 MSEK is to help Ziccum develop the scale-up of LaminarPace. The spray drying tool dries vaccines, peptides and biologics at room temperature—transforming them into robust, easy-to-transport dry powders. The technology could lead to the development of a new generation of novel, stable, worldwide therapies, with IP rights built on LaminarPace.
Ziccum AB’s new Board of Directors includes the Head of Life Science at Chalmers Ventures, and a Senior Advisor at Karolinska Institutet Innovation AB. “The business and scientific calibre of our new members is a powerful vote of confidence in our product, market and vision,” says Ziccum CEO Göran Conradson.
STOCKHOLM, SWEDEN – 19 April, 2018. Inhalation Sciences, who develop and sell world-leading labtech for inhalation research, announces Lena Heffler as its new CEO. Lena officially takes up her new role on 7 May 2018.
80% of human immunoglobulin antibodies, used to treat a wide range of diseases, are formulated as liquids, which can mean they are fragile, unstable and costly to transport. New results show that Ziccum AB’s spray drying instrument LaminarPace can produce a stable dry powder form of immunoglobulin antibodies—with confirmed activity. ‘This is an important milestone,’ says Ziccum CEO Göran Conradson.